COLORADO DENVER UNIVERSITY OF

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Bryostatin 1 in Treating Patients With Stage IV Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer

First Posted Date: 2003-04-23

Last Posted Date: 2013-05-30

Lead Sponsor: University of Colorado, Denver

Registration Number: NCT00003205

Locations: 🇺🇸
University of Colorado Cancer Center, Denver, Colorado, United States

13-Cis Retinoic Acid With or Without Vitamin E for Prevention of Lung Cancer

Phase 2

Completed

Conditions: Drug Toxicity
Lung Cancer

Interventions: Drug: 13-cis retinoic acid
Dietary Supplement: Tocopherol

First Posted Date: 2003-01-27

Last Posted Date: 2020-05-15

Lead Sponsor: University of Colorado, Denver

Target Recruit Count: 96

Registration Number: NCT00002586

Locations: 🇺🇸
Lung Cancer Institute, Denver, Colorado, United States
🇺🇸
University of Colorado Cancer Center at University of Colorado Health Sciences Center, Denver, Colorado, United States
🇺🇸
National Jewish Center for Immunology and Respiratory Medicine, Denver, Colorado, United States

and more 1 locations

Embryonic Dopamine Cell Implants for Parkinson's Disease

Phase 3

Completed

Conditions: Parkinson Disease

Interventions: Procedure: embryonic dopamine cell implant surgery
Procedure: placebo

First Posted Date: 2002-05-30

Last Posted Date: 2013-02-05

Lead Sponsor: University of Colorado, Denver

Target Recruit Count: 40

Registration Number: NCT00038116

Locations: 🇺🇸
University Hospital, the University of Colorado Health Sciences Center, Denver, Colorado, United States
🇺🇸
North Shore University Hospital, Manhasset, New York, United States
🇺🇸
The Movement Disorder Center, Columbia-Presbyterian Hospital, New York, New York, United States

Inhaled Nitric Oxide for Preventing Chronic Lung Disease in Premature Infants

Phase 3

Completed

Conditions: Lung Diseases
Bronchopulmonary Dysplasia

Interventions: Other: Placebo
Drug: iNO

First Posted Date: 2000-10-13

Last Posted Date: 2015-10-06

Lead Sponsor: University of Colorado, Denver

Target Recruit Count: 793

Registration Number: NCT00006401

Locations: 🇺🇸
Univeristy of Southern California/Good Samaritan Hospital, Los Angeles, California, United States
🇺🇸
University of Iowa Hospital & Clinics, Iowa City, Iowa, United States
🇺🇸
University of North Carolina Chapel Hill, Chapel Hill, North Carolina, United States

and more 11 locations

Coronary Artery Calcification in Type 1 Diabetes

Completed

Conditions: Cardiovascular Diseases
Diabetes Mellitus
Heart Diseases
Coronary Disease
Diabetes Mellitus, Insulin-dependent

First Posted Date: 2000-05-26

Last Posted Date: 2015-06-10

Lead Sponsor: University of Colorado, Denver

Target Recruit Count: 1420

Registration Number: NCT00005754

Buprenorphine/Naloxone Treatment for Opioid Dependence-Experiment III) - 3

Phase 2

Withdrawn

Conditions: Heroin Dependence
Opioid-Related Disorders

First Posted Date: 1999-09-21

Last Posted Date: 2017-05-04

Lead Sponsor: University of Colorado, Denver

Registration Number: NCT00000328

Locations: 🇺🇸
University of Colorado Health Sciences Center, Denver, Colorado, United States

Buprenorphine/Naloxone Treatment for Opioid Dependence-Experiment II-2 - 5

Phase 2

Withdrawn

Conditions: Opioid-Related Disorders
Heroin Dependence

First Posted Date: 1999-09-21

Last Posted Date: 2017-05-04

Lead Sponsor: University of Colorado, Denver

Registration Number: NCT00000330

Locations: 🇺🇸
University of Colorado Health Sciences Center, Denver, Colorado, United States

Buprenorphine/Naloxone Treatment for Opioid Dependence-Experiment II-3 - 6

Phase 2

Withdrawn

Conditions: Heroin Dependence
Opioid-Related Disorders

Interventions: Drug: Placebo Drug
Drug: Test Drug

First Posted Date: 1999-09-21

Last Posted Date: 2017-05-04

Lead Sponsor: University of Colorado, Denver

Registration Number: NCT00000331

Locations: 🇺🇸
University of Colorado Health Sciences Center, Denver, Colorado, United States

Buprenorphine/Naloxone Treatment for Opioid Dependence-Experiment II-1 - 4

Phase 2

Withdrawn

Conditions: Opioid-Related Disorders
Heroin Dependence

First Posted Date: 1999-09-21

Last Posted Date: 2017-05-04

Lead Sponsor: University of Colorado, Denver

Registration Number: NCT00000329

Locations: 🇺🇸
University of Colorado Health Sciences Center, Denver, Colorado, United States

Buprenorphine/Naloxone Treatment for Opioid Dependence-Experiment I(2) - 2

Phase 2

Withdrawn

Conditions: Opioid-Related Disorders
Heroin Dependence

First Posted Date: 1999-09-21

Last Posted Date: 2017-05-04

Lead Sponsor: University of Colorado, Denver

Registration Number: NCT00000327

Locations: 🇺🇸
University of Colorado Health Sciences Center, Denver, Colorado, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy